» Articles » PMID: 22728209

Centrally Administered Apelin-13 Induces Depression-like Behavior in Mice

Overview
Journal Brain Res Bull
Specialty Neurology
Date 2012 Jun 26
PMID 22728209
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Apelin, a novel bioactive peptide highly concentrated in the brain, is identified as the endogenous ligand for angiotensin-like 1 receptor (APJ). The present study was designed to investigate the effect of apelin-13 on emotion-related behavior using the forced swimming test (FST) and tail suspension test (TST). Intracerebroventricular (i.c.v.) administration of apelin-13 (0.3, 1 and 3μg/mouse) dose-dependently increased the immobility time in the FST and TST, compared with control group. However, the APJ receptor antagonist apelin-13(F13A) (0.3-10μg/mouse, i.c.v.) had no influence on immobility time in the FST. The increase of immobility time induced by apelin-13 was significantly blocked by apelin-13(F13A), non-selective opioid receptor antagonist naloxone and κ-opioid receptor antagonist nor-binaltorphimine dihydrochloride (nor-BNI), respectively, but not the non-selective corticotrophin-releasing factor (CRF) receptor antagonist α-helical CRF(9-41) in the FST. In order to eliminate the possibility of a false-positive result in the FST or TST, spontaneous activity and motor function were checked. The results demonstrate that apelin-13 alone or antagonists co-administered with apelin-13 did influence spontaneous activity counts. And apelin-13 had no effect on the motor behavior in the rotarod test and wire hanging test. These results indicate that centrally administered apelin-13 elicited depression-like behavior in mice, which was mediated via APJ receptor and κ-opioid receptor, but not CRF receptor.

Citing Articles

Evaluating Apelin as a Potential Biomarker in Major Depressive Disorder: Its Correlation with Clinical Symptomatology.

Chibaatar E, Fujii R, Ikenouchi A, Okamoto N, Natsuyama T, Hayasaki G Int J Mol Sci. 2025; 25(24.

PMID: 39769424 PMC: 11727983. DOI: 10.3390/ijms252413663.


Polypyrimidine tract binding protein knockdown reverses depression-like behaviors and cognition impairment in mice with lesioned cholinergic neurons.

Zhou Y, Zhang K, Wang F, Chen J, Chen S, Wu M Front Aging Neurosci. 2023; 15:1174341.

PMID: 37181622 PMC: 10172502. DOI: 10.3389/fnagi.2023.1174341.


Neuroprotective Roles of Apelin-13 in Neurological Diseases.

Zhang Y, Jiang W, Sun W, Guo W, Xia B, Shen X Neurochem Res. 2023; 48(6):1648-1662.

PMID: 36745269 DOI: 10.1007/s11064-023-03869-0.


Interaction of apelin, elabela and nitric oxide in schizophrenia patients.

Catak Z, Kaya H, Kocdemir E, Ugur K, Pilten G, Yardim M J Med Biochem. 2020; 39(2):184-190.

PMID: 33033451 PMC: 7526016. DOI: 10.2478/jomb-2019-0029.


Association of Apelin and Apelin Receptor Polymorphisms With the Risk of Comorbid Depression and Anxiety in Coronary Heart Disease Patients.

Wang Y, Liu W, Xiao Y, Yuan H, Wang F, Jiang P Front Genet. 2020; 11:893.

PMID: 32849850 PMC: 7432257. DOI: 10.3389/fgene.2020.00893.